Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy.

ABSTRACT:

Background

Current recommendations for monitoring patients with chronic myeloid leukemia (CML) provide recommendations for response assessment and treatment only at 3, 6, 12, and 18 months. These recommendations are based on clinical trial outcomes computed from treatment start. Conditional survival estimates take into account the changing hazard rates as time from treatment elapses as a continuum.

Patients and methods

We performed conditional survival analyses among patients with CML to improve prognostication at any time point during the course of therapy. We used 2 cohorts of patients with CML in chronic phase: 1 treated in the frontline DASISION (Dasatinib versus Imatinib Study in Treatment - Naïve CML) phase III study (n = 519) and another treated after imatinib treatme

SUBMITTER: Quintas-Cardama A 

PROVIDER: S-EPMC4099320 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature